logo-loader

4D pharma says asthma live biotherapeutic shows ‘promising’ early signs of clinical activity

Published: 02:56 13 Dec 2021 EST

4D pharma PLC -

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said its live biotherapeutic for asthma showed ‘promising’ signs of clinical activity in the very initial stages of the clinical trial process.

Part A of the phase I/II study was designed to assess the safety and tolerability of MRx-4DP0004 – and did so. No serious adverse events were reported.

Having detected the signs of clinical activity, 4D will push into Part B of the evaluation, which will recruit 90 asthma sufferers to assess further the potential efficacy of the drug.

Chief scientific officer Alex Stevenson called the latest results an ‘important step forward’ in the development of a new asthma treatment.

"Not only do the results support the excellent safety profile shown to date across our clinical pipeline of live biotherapeutics for a variety of indications, but also demonstrate our ability to identify and develop single strain LBPs with potent systemic activity using our MicroRx platform.

“MRx-4DP0004 has shown encouraging activity in key secondary endpoints of clinical activity, and this data will help to guide the selection of patients for future development of the product."

The group generates live biotherapeutics from good bacteria strains taken from the human microbiome, which resides mainly in the gut.

 

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

3 hours, 25 minutes ago